A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.

Name: Αlpha¹ Rigor Record — A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
Item: A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
Rating: 59
Author: Αlpha¹

Chen WH, Barnes RS, Sikorski MJ, Datar R, Sukhavasi R, Liang Y, Rapaka RR, Pasetti MF, Sztein MB, Wahid R, Tennant SM, Simon R, Baliban SM, Galen JE, Lees A, Bernshtein B, Alter G, Ella R, Mohan K, Naidu MG, Rao DY, Ella KM, Levine MM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 5 high issues for “A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
StatisticsStatistic did not reproduce−0.5★
ReportingStudy design partially met−0.25★
ReportingStatistical analysis partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.39.0Source: full text

Problems surfaced7 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted first-in-human phase 1 trial of a trivalent Salmonella conjugate vaccine, with strong scientific premise, adequate ethical approvals, and transparent reporting. The main weaknesses are incomplete reporting of randomization and blinding details, lack of a formal power analysis, imprecise statistical reporting (threshold p-values, no effect sizes with CIs), and a vague data availability statement.

All three reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text, with verification components checking citations (32 references, none retracted or missing), statistics (2 tests recomputed, 1 consistent, 1 inconsistent), reproducibility (2 links live), and preregistration (ClinicalTrials.gov, CONSORT). The statistics coverage is limited to tests with test statistics and df; threshold-only p-values and resampling-based tests were not machine-verified. The reviewers diverged on study design and statistical analysis (pass vs. warn), but the synthesized status is warn based on the checklist-level gaps.

12 major claims checked against the paper's own evidence: 4 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions5 pass · 3 warn

The introduction extensively cites epidemiological data on iNTS and typhoid burden, prior vaccine development efforts, and preclinical studies in mice and rabbits demonstrating immunogenicity and protection. The rationale for combining Vi-TT with iNTS COPS:FliC conjugates is logically presented. Limitations of prior work (e.g., lack of a combined vaccine, need for a vaccine suitable for infants) are implicitly addressed by the study's objectives, though not explicitly discussed as limitations of prior research.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing the burden of invasive non-typhoidal Salmonella and typhoid in sub-Saharan Africa, prior preclinical studies, and the rationale for a trivalent vaccine.

Evidence

direct quote[Introduction, paragraph 1]

“In 2017 it was estimated that globally ˜535,000 cases of iNTS disease occurred in persons not infected with HIV, of which ˜421,600 transpired in SSA, accompanied by ˜66,520 deaths.”